ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s layoffs
Plus, news about Cognition Therapeutics, Sagimet Biosciences, BeiGene, Hikma and Rallybio: ALX Oncology won’t pursue approval in gastric cancer: The company had been aiming to get its CD47-targeting drug, called evorpacept, an accelerated approval in ...
Plus, news about Cognition Therapeutics, Sagimet Biosciences, BeiGene, Hikma and Rallybio:
ALX Oncology won’t pursue approval in gastric cancer: The company had been aiming to get its CD47-targeting drug, called evorpacept, an accelerated approval in ...
